Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial

V. Torri | S. Marino | R. Pallini | E. Beghi | L. Tassi | E. Mazzon | M. Lampugnani | E. Dejana | R. Salman | A. Maggioni | R. Latini | R. Al‐Shahi Salman | C. Fusco | E. Mazzon | A. Petracca | M. Castori | E. Scola | S. Lanfranconi | R. Treglia | G. Faragò | F. Pignotti | L. D'agruma | E. Scelzo | R. Ciurleo | D. Novelli | M. Mangiavacchi | M. Malinverno | S. Marino | M. Tettamanti | C. Ungaro | M. Carriero | F. Lazzaroni | B. Zarino | P. d’Orio | E. Nicolis | U. de Grazia | G. Bertani | M. L. Fernandez | M. Poloni | G. Balconi | D. Ronchi | A. Prelle | J. Meessen | A. Vasamì | G. Valcamonica | S. Pogliani | A. Foresta | V. Torri | G. d’Alessandris | R. G. F. C. A. S. E. G. A. B. G. D. M. R. E. G. S. U. Pallini d’Alessandris Pignotti Sturiale Albane | C. Sturiale | A. Albanese | C. Bossi | C. Fusco | P. Raggi | A. Simeone | M. Buratti | M. Carrara | C. Regna-Gladin | F. Raucci | L. Tassi | Piergiorgio d’Orio | P. d’Orio | R. Pallini | Barbara Zarino | Giorgio d’Alessandris | Giuseppe Faragò | Leonardo d’Agruma | Enrico Bjorn Nicolis | Antonella Vasamì | G. d’Alessandris | B. Zarino | G. Faragò | L. D’Agruma | E. B. Nicolis | A. Vasamì | A. Vasami | E. Dejana | M. Castori | S. Lanfranconi | E. Scola | G. A. Bertani | R. Pallini | E. Mazzon | S. Marino | M. R. Carriero | E. Scelzo | G. Faragò | C. Fusco | L. Tassi | E. B. Nicolis | V. Torri | R. Latini | E. Scola | G. A. Bertani | R. Pallini | E. Mazzon | S. Marino | M. R. Carriero | E. Scelzo | G. Faragò | C. Fusco | V. Torri | M. L. Fernández

[1]  C. Lengner,et al.  Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation , 2019, Science Translational Medicine.

[2]  L. Morrison,et al.  Familial Cerebral Cavernous Malformations , 2019, Stroke.

[3]  L. Morrison,et al.  Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. , 2018, Neurosurgery.

[4]  C. Sudlow,et al.  Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis , 2018, British Medical Journal.

[5]  Dean Y. Li,et al.  Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations , 2018, Translational Stroke Research.

[6]  Huan Tan,et al.  Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. , 2017, Journal of neurosurgery.

[7]  C. Jack,et al.  Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging , 2017, JAMA neurology.

[8]  B. Miller,et al.  Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. , 2017, The New England journal of medicine.

[9]  Dean Y. Li,et al.  Endothelial TLR4 and the microbiome drive cerebral cavernous malformations , 2017, Nature.

[10]  D. Kondziolka,et al.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel , 2017, Neurosurgery.

[11]  R. Du,et al.  Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. , 2017, Journal of neurosurgery.

[12]  Rachel B. Keller,et al.  Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. , 2016, JCI insight.

[13]  L. Morrison,et al.  Cerebral Cavernous Malformation, Familial , 2016 .

[14]  R. Spetzler,et al.  Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. , 2016, World neurosurgery.

[15]  A. Algra,et al.  Prognosis of cerebral cavernomas: on to treatment decisions , 2016, The Lancet Neurology.

[16]  Robert D. Brown,et al.  Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data , 2016, The Lancet Neurology.

[17]  Bruno Amati,et al.  Degradation dynamics of microRNAs revealed by a novel pulse-chase approach , 2016, Genome research.

[18]  S. Prey,et al.  Safety of Propranolol Therapy for Severe Infantile Hemangioma. , 2016, JAMA.

[19]  R. Shenkar,et al.  Vascular Permeability in Cerebral Cavernous Malformations , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  C. Berul,et al.  A randomized, controlled trial of oral propranolol in infantile hemangioma. , 2015, The New England journal of medicine.

[21]  Y. E. Chen,et al.  Non-coding RNAs in cerebral endothelial pathophysiology: Emerging roles in stroke , 2014, Neurochemistry International.

[22]  F. Jiang,et al.  Circulating microRNAs Serve as Novel Biological Markers for Intracranial Aneurysms , 2014, Journal of the American Heart Association.

[23]  C. Warlow,et al.  Outcome after surgical or conservative management of cerebral cavernous malformations , 2014, Neurology.

[24]  Jon Thacker,et al.  Evaluation of Iron Content in Human Cerebral Cavernous Malformation Using Quantitative Susceptibility Mapping , 2014, Investigative radiology.

[25]  A. Dupuy,et al.  Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol. , 2014, Journal of the American Academy of Dermatology.

[26]  D. Zanon,et al.  Propranolol for Cerebral Cavernous Angiomatosis , 2014, Clinical pediatrics.

[27]  L. Ferrarini,et al.  EndMT contributes to the onset and progression of cerebral cavernous malformations , 2013, Nature.

[28]  D. Torgerson,et al.  Sample size calculations for pilot randomized trials: a confidence interval approach. , 2013, Journal of clinical epidemiology.

[29]  K. Holland,et al.  Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference , 2013, Pediatrics.

[30]  L. S. Schultze Kool,et al.  Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. , 2011, Journal of the American Academy of Dermatology.

[31]  H. Kraemer,et al.  The role and interpretation of pilot studies in clinical research. , 2011, Journal of psychiatric research.

[32]  G. Zipfel,et al.  Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation. , 2010, Neurosurgical focus.

[33]  M. Moschovi,et al.  Propranolol Treatment for a Giant Infantile Brain Cavernoma , 2010, Journal of child neurology.

[34]  W. Min,et al.  Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development , 2010, Science Signaling.

[35]  Yoshito Tsushima,et al.  Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.

[36]  G. Steinberg,et al.  Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. , 2009, Human molecular genetics.

[37]  Elisabetta Dejana,et al.  The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. , 2009, Developmental cell.

[38]  U. Felbor,et al.  A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells , 2008, Human molecular genetics.

[39]  L. Morrison,et al.  Hemorrhage From Cavernous Malformations of the Brain: Definition and Reporting Standards , 2008, Stroke.

[40]  E. Tournier-Lasserve,et al.  Genetics of cavernous angiomas , 2007, The Lancet Neurology.

[41]  J. Gault,et al.  Biallelic Somatic and Germ Line CCM1 Truncating Mutations in a Cerebral Cavernous Malformation Lesion , 2005, Stroke.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[43]  Fiona Peachey,et al.  Data management and statistical analysis , 2000 .

[44]  L. Brunereau,et al.  Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families , 1998, The Lancet.

[45]  R F Spetzler,et al.  The natural history of familial cavernous malformations: results of an ongoing study. , 1994, Journal of neurosurgery.

[46]  A M Rhodes,et al.  Treatment decisions. , 1991, MCN. The American journal of maternal child nursing.

[47]  Williams Ia.  Letter: Levamisole and agranulocytosis. , 1976 .

[48]  J. Black,et al.  Preliminary CommunicationsA NEW ADRENERGIC: BETA-RECEPTOR ANTAGONIST , 1964 .

[49]  J. Black,et al.  A NEW ADRENERGIC , 1964 .

[50]  J. Black,et al.  A NEW ADRENERGIC BETARECEPTOR ANTAGONIST. , 1964, Lancet.